NZ599878A - Anticancer combination of artemisinin-based drugs and other chemotherapeutic agents - Google Patents
Anticancer combination of artemisinin-based drugs and other chemotherapeutic agentsInfo
- Publication number
- NZ599878A NZ599878A NZ599878A NZ59987810A NZ599878A NZ 599878 A NZ599878 A NZ 599878A NZ 599878 A NZ599878 A NZ 599878A NZ 59987810 A NZ59987810 A NZ 59987810A NZ 599878 A NZ599878 A NZ 599878A
- Authority
- NZ
- New Zealand
- Prior art keywords
- group
- artemisinin
- chemotherapeutic agents
- combinations
- based drugs
- Prior art date
Links
- 229960004191 artemisinin Drugs 0.000 title abstract 4
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 title abstract 4
- 229930101531 artemisinin Natural products 0.000 title abstract 4
- 239000002246 antineoplastic agent Substances 0.000 title abstract 2
- 239000012635 anticancer drug combination Substances 0.000 title 1
- 229940046044 combinations of antineoplastic agent Drugs 0.000 title 1
- 229940127089 cytotoxic agent Drugs 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 abstract 2
- 229960000981 artemether Drugs 0.000 abstract 2
- SXYIRMFQILZOAM-HVNFFKDJSA-N dihydroartemisinin methyl ether Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OC)O[C@H]4[C@]32OO[C@@]1(C)O4 SXYIRMFQILZOAM-HVNFFKDJSA-N 0.000 abstract 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 abstract 1
- 108010092160 Dactinomycin Proteins 0.000 abstract 1
- BJDCWCLMFKKGEE-KDTBHNEXSA-N Dihydroartemisinin (DHA) Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](O)[C@@H]4C BJDCWCLMFKKGEE-KDTBHNEXSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 abstract 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 abstract 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 abstract 1
- 229940100198 alkylating agent Drugs 0.000 abstract 1
- 239000002168 alkylating agent Substances 0.000 abstract 1
- 239000003430 antimalarial agent Substances 0.000 abstract 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229960004562 carboplatin Drugs 0.000 abstract 1
- 190000008236 carboplatin Chemical compound 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229940044683 chemotherapy drug Drugs 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229960000640 dactinomycin Drugs 0.000 abstract 1
- 229960000975 daunorubicin Drugs 0.000 abstract 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 abstract 1
- 229960004679 doxorubicin Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000009830 intercalation Methods 0.000 abstract 1
- 229950007221 nedaplatin Drugs 0.000 abstract 1
- 190000005734 nedaplatin Chemical compound 0.000 abstract 1
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 abstract 1
- 229950011068 niraparib Drugs 0.000 abstract 1
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 abstract 1
- 229960000572 olaparib Drugs 0.000 abstract 1
- 229960001756 oxaliplatin Drugs 0.000 abstract 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 abstract 1
- RZFVLEJOHSLEFR-UHFFFAOYSA-N phenanthridone Chemical compound C1=CC=C2C(O)=NC3=CC=CC=C3C2=C1 RZFVLEJOHSLEFR-UHFFFAOYSA-N 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 229960005399 satraplatin Drugs 0.000 abstract 1
- 190014017285 satraplatin Chemical compound 0.000 abstract 1
- 229950011257 veliparib Drugs 0.000 abstract 1
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09180666 | 2009-12-23 | ||
| PCT/EP2010/068924 WO2011076547A1 (en) | 2009-12-23 | 2010-12-06 | Anticancer combination of artemisinin-based drugs and other chemotherapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ599878A true NZ599878A (en) | 2014-06-27 |
Family
ID=41647059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ599878A NZ599878A (en) | 2009-12-23 | 2010-12-06 | Anticancer combination of artemisinin-based drugs and other chemotherapeutic agents |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9023861B2 (enExample) |
| EP (1) | EP2515898A1 (enExample) |
| JP (1) | JP2013515690A (enExample) |
| KR (1) | KR20120096053A (enExample) |
| CN (1) | CN102665711A (enExample) |
| AR (1) | AR079654A1 (enExample) |
| AU (1) | AU2010335422A1 (enExample) |
| BR (1) | BR112012015606A2 (enExample) |
| CA (1) | CA2780591A1 (enExample) |
| EA (1) | EA201200934A1 (enExample) |
| IL (1) | IL220561A0 (enExample) |
| IN (1) | IN2012DN03914A (enExample) |
| MX (1) | MX2012006738A (enExample) |
| MY (1) | MY157475A (enExample) |
| NZ (1) | NZ599878A (enExample) |
| PH (1) | PH12012500893A1 (enExample) |
| SG (1) | SG10201408485SA (enExample) |
| TW (1) | TWI482621B (enExample) |
| UA (1) | UA107691C2 (enExample) |
| WO (1) | WO2011076547A1 (enExample) |
| ZA (1) | ZA201205360B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9314473B2 (en) | 2011-02-03 | 2016-04-19 | Pop Test Oncology Limited Liability Company | System and method for diagnosis and treatment |
| US9801851B2 (en) * | 2012-05-23 | 2017-10-31 | St. Jude Children's Research Hospital | Methods and compositions for the treatment of BCR-ABL positive lymphoblastic leukemias |
| EP3137076A4 (en) * | 2014-05-02 | 2017-12-06 | Emory University | Selective chemotherapy treatments and diagnostic methods related thereto |
| US9918972B2 (en) * | 2014-12-23 | 2018-03-20 | The University Of Maryland, Baltimore | Treatment of leukemia with artemisinin derivatives and combinations with other antineoplastic agents |
| CN105963262B (zh) * | 2016-06-06 | 2018-11-30 | 北京林业大学 | 一种两亲性果胶-双氢青蒿素纳米粒子的制备方法 |
| CN110051850A (zh) * | 2016-08-26 | 2019-07-26 | 宁国市厚普生物科技有限公司 | 一种复合物在制备用于治疗黑色素瘤的药物中的应用 |
| CN109453156A (zh) * | 2018-11-22 | 2019-03-12 | 中国中医科学院中药研究所 | 一种抗肿瘤组合物及其应用、抗肿瘤药物 |
| EP3868372A1 (en) * | 2020-02-19 | 2021-08-25 | JLP Health GmbH | A pharmaceutical combination of an artemisinin compound and a heme synthesis modulator for treating cancer |
| CN114053276B (zh) * | 2020-07-30 | 2024-05-07 | 江苏天士力帝益药业有限公司 | 一种parp抑制剂tsl-1502中间体tsl-1502m的用途 |
| CN114053271B (zh) * | 2020-07-30 | 2024-05-07 | 江苏天士力帝益药业有限公司 | 一种含有tsl-1502m的药物组合物及其应用 |
| CN114010643A (zh) * | 2021-11-23 | 2022-02-08 | 温州医科大学 | 双氢青蒿素在抗肿瘤药物的制备中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5578637A (en) | 1995-05-03 | 1996-11-26 | University Of Washington | Methods of inhibition or killing cancer cells using an endoperoxide |
| SI1044977T1 (en) | 1999-03-09 | 2002-08-31 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Camptothecin derivatives having antitumor activity |
| KR100390332B1 (ko) | 2000-08-02 | 2003-07-07 | 유원민 | 항말라리아제와 항암제의 병용투여에 의한 항암제 복합 조성물 |
| WO2004071506A1 (en) * | 2003-02-12 | 2004-08-26 | Georgetown University | Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections |
| EP1658844A1 (en) | 2004-10-19 | 2006-05-24 | Gerold Schuler | Use of artemisinin derivatives in the manufacture of a medicament for the treatment of melanoma |
| TWI375673B (en) | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| US8143284B2 (en) * | 2006-10-05 | 2012-03-27 | Abbott Laboratories | Poly(ADP-ribose)polymerase inhibitors |
| WO2008063644A1 (en) | 2006-11-20 | 2008-05-29 | Cephalon, Inc. | Method of radio-sensitizing tumors using a radio-sensitizing agent |
| CN101125140B (zh) * | 2007-09-18 | 2011-04-13 | 浙江大学 | 二氢青蒿素在制备增强化疗药物抗肿瘤疗效的药物中的应用 |
| WO2009114459A2 (en) * | 2008-03-10 | 2009-09-17 | The Trustees Of The University Of Pennsylvania | Anti-neoplastic combination therapeutic regimen involving co-disruption of parp pathway and mre11/rad50/nbs1 complex and compositons useful therein |
| CN101380325A (zh) * | 2008-10-23 | 2009-03-11 | 上海交通大学 | 青蒿素衍生物与长春瑞滨的组合物及其应用 |
| CN101428034B (zh) * | 2008-12-12 | 2012-02-08 | 广州市允中投资发展有限公司 | 具有增效减毒特点的抗肿瘤组合药物 |
| CN101856352A (zh) * | 2009-04-10 | 2010-10-13 | 中国科学院上海生命科学研究院 | 青蒿素及其衍生物对化疗剂的协同作用 |
-
2010
- 2010-11-22 TW TW099140203A patent/TWI482621B/zh not_active IP Right Cessation
- 2010-12-06 UA UAA201208932A patent/UA107691C2/ru unknown
- 2010-12-06 WO PCT/EP2010/068924 patent/WO2011076547A1/en not_active Ceased
- 2010-12-06 US US13/518,185 patent/US9023861B2/en not_active Expired - Fee Related
- 2010-12-06 JP JP2012545201A patent/JP2013515690A/ja not_active Ceased
- 2010-12-06 IN IN3914DEN2012 patent/IN2012DN03914A/en unknown
- 2010-12-06 MX MX2012006738A patent/MX2012006738A/es not_active Application Discontinuation
- 2010-12-06 CN CN2010800580524A patent/CN102665711A/zh active Pending
- 2010-12-06 NZ NZ599878A patent/NZ599878A/en not_active IP Right Cessation
- 2010-12-06 AU AU2010335422A patent/AU2010335422A1/en not_active Abandoned
- 2010-12-06 PH PH1/2012/500893A patent/PH12012500893A1/en unknown
- 2010-12-06 CA CA2780591A patent/CA2780591A1/en not_active Abandoned
- 2010-12-06 KR KR1020127016599A patent/KR20120096053A/ko not_active Withdrawn
- 2010-12-06 SG SG10201408485SA patent/SG10201408485SA/en unknown
- 2010-12-06 BR BR112012015606A patent/BR112012015606A2/pt not_active IP Right Cessation
- 2010-12-06 EP EP10788312A patent/EP2515898A1/en not_active Withdrawn
- 2010-12-06 EA EA201200934A patent/EA201200934A1/ru unknown
- 2010-12-06 MY MYPI2012001992A patent/MY157475A/en unknown
- 2010-12-21 AR ARP100104807A patent/AR079654A1/es unknown
-
2012
- 2012-06-21 IL IL220561A patent/IL220561A0/en unknown
- 2012-07-18 ZA ZA2012/05360A patent/ZA201205360B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12012500893A1 (en) | 2012-11-12 |
| US9023861B2 (en) | 2015-05-05 |
| KR20120096053A (ko) | 2012-08-29 |
| MY157475A (en) | 2016-06-15 |
| EA201200934A1 (ru) | 2012-12-28 |
| BR112012015606A2 (pt) | 2018-05-29 |
| UA107691C2 (ru) | 2015-02-10 |
| MX2012006738A (es) | 2012-07-03 |
| SG10201408485SA (en) | 2015-01-29 |
| ZA201205360B (en) | 2013-05-29 |
| CA2780591A1 (en) | 2011-06-30 |
| EP2515898A1 (en) | 2012-10-31 |
| IN2012DN03914A (enExample) | 2015-09-04 |
| AR079654A1 (es) | 2012-02-08 |
| US20120258181A1 (en) | 2012-10-11 |
| JP2013515690A (ja) | 2013-05-09 |
| CN102665711A (zh) | 2012-09-12 |
| IL220561A0 (en) | 2012-08-30 |
| AU2010335422A1 (en) | 2012-06-07 |
| TWI482621B (zh) | 2015-05-01 |
| TW201138764A (en) | 2011-11-16 |
| WO2011076547A1 (en) | 2011-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ599878A (en) | Anticancer combination of artemisinin-based drugs and other chemotherapeutic agents | |
| WO2008081927A1 (ja) | 抗癌剤の併用による癌治療方法 | |
| JP2010180210A5 (enExample) | ||
| EP4335511A3 (en) | Small molecule trail gene induction by normal and tumor cells as an anticancer therapy | |
| EP2431369A3 (en) | Carboline derivatives useful in the inhibition of angiogenesis | |
| WO2007139930A3 (en) | Drug combinations with substituted diaryl ureas for the treatment of cancer | |
| WO2009140675A3 (en) | Combination therapy with pm00104 and another antitumor agent | |
| WO2008094321A3 (en) | Akt sensitization of cancer cells | |
| IL201284A (en) | K3pi alpha pyridopyrimidinone inhibitor for use in combination with one or more therapeutic agents selected from Taxol, Rapamycin, Carboplatin and Arlutinib for cancer treatment | |
| WO2012065085A4 (en) | Methods of treating cancer | |
| RU2006122350A (ru) | Комбинированная химиотерапия | |
| WO2011054837A3 (de) | Bifunktionale prodrugs und drugs | |
| EP2816114A3 (en) | MicroRNAs and uses thereof | |
| RU2019105574A (ru) | Противоопухолевый агент, усилитель противоопухолевого действия и противоопухолевый набор | |
| EP2277884A8 (en) | Anthracycline antibiotic derivatives with high activity, preparation methods and uses thereof | |
| JP2007277240A5 (enExample) | ||
| CO6390103A2 (es) | Combinación antitumoral que comprende cabazitaxel y capecitabina | |
| WO2010108251A3 (pt) | Complexo molecular antineoplásico-testosterona | |
| WO2011017096A3 (en) | Methods of treating hematologic cancers | |
| Sun et al. | Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells | |
| NO20063987L (no) | Anti-cancerterapier | |
| Hu et al. | Current status of CPT and its analogues in the treatment of malignancies | |
| Xingsheng et al. | Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer | |
| HK1200330A1 (en) | Romidepsin and 5 - azacitidine for use in treating lymphoma | |
| WO2013044028A3 (en) | Mycophenolic acid analogues as anti-tumor chemosensitizing agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 DEC 2015 BY COMPUTER PACKAGES INC Effective date: 20141118 |
|
| LAPS | Patent lapsed |